US equities |
MU $1,078.55 ▲+1.26% NVDA $231.24 ▲+1.25% SNDK $1,775.61 ▲+2.05% INTC $121.00 ▲+0.64% TSLA $357.08 ▲+0.64% GOOGL $338.67 ▼-1.57% SPCX $150.01 ▼-0.56% AMD $616.22 ▲+0.73%
FinancialContent Watchlist

Candel Therapeutics, Inc. - Common Stock (NQ:CADL)

10.35 -0.09 (-0.86%)
Delayed Quote Updated: 2:31 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Candel Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at September Investor Conferences
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Canaccord Genuity’s 46th Annual Growth Conference in Boston
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Initiation of Global Pivotal Phase 3 AURORA Trial Evaluating Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Appoints Mark Sims as Chief Commercial Officer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Publication in The Lancet Oncology of Pivotal Phase 3 Data Demonstrating Significant Improvement in Disease-Free Survival with Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Extended Clinical Benefit Over Multiple Clinical Endpoints in Patients from Phase 3 Trial of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer Under Prolonged Follow-up at AUA 2026 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at Upcoming Investor Conferences
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Host Investor Conference Call Following Presentation of Extended Data from Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Commercialization Agreement with EVERSANA to Support Potential U.S. Launch of Aglatimagene Besadenovec in Localized Prostate Cancer
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Extended Survival Tail Observed in Trial of Aglatimagene Besadenovec (CAN-2409) in Advanced Non-Small Cell Lung Cancer Patients with Inadequate Response to Immune Checkpoint Inhibitors
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics to Present at TD Cowen’s 46th Annual Health Care Conference in Boston
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Pricing of Public Offering
From Candel Therapeutics
Via GlobeNewswire
News headline image
Candel Therapeutics Announces Proposed $100 Million Public Offering
From Candel Therapeutics
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >